Partner Campus Event: Thermo Fisher Scientific Presenting at Rutgers.

End-User Forum dedicated to Extrusion-Enabled Pharmaceutical Processes (E2P2)

“Thermo Fisher Scientific invites you to join and actively contribute to an end-user forum dedicated to extrusion-enabled pharmaceutical processes and technologies.”

Thursday, November 9, 2017 8:30 a.m. – 4:30 p.m.

Rutgers University,

Busch Campus Center, Room 174,

604 Bartholomew Rd,

Piscataway Township, NJ 08854, USA

Thermo Fisher Scientific is hosting an End-User Forum dedicated to extrusion-enabled pharmaceutical technologies: HME, TSG (melt granulation & wet granulation), continuous manufacturing, etc at Rutgers University.

  • Who should attend: current and future practitioners of extrusion-enabled pharmaceutical processes keen to share their experience with all participants and to create an end-user forum for all to enrich their knowledge in this exciting and fast-evolving space

  • Following organizations will be presenting: Merck & Co, Aurobindo, BASF, MilliporeSigma, Glatt, Hovione, St. John’s University, Rutgers University, Thermo Fisher Scientific, etc.

  • Presentations, round-table discussions and Q&A sessions dedicated to:

a) Best practices in hot melt extrusion and twin screw granulation

b) Recent advances in polymers for oral dosage forms

c) Implant development and production platforms

d) Enabling of continuous pharmaceutical manufacturing

The event will offer an excellent learning and networking opportunity. You will also have a chance to meet with representatives from Patheon, the newest member of the Thermo Fisher network. There is no fee to attend; advance online registration is requested for both presenters and attendees!

For a complete event agenda please refer to attached document.

 
 

For questions, comments, or assistance of any type contact C-SOPS at info@csops.org or 848-445-6709/ 848-445-6710

#ContinuousManufacturing #ThermoFisherScientific #EndUser #Forum #2017

Featured Posts
Recent Posts
Archive
Search By Tags
No tags yet.
Follow Us</